Goodwin R J A, Bunch J, McGinnity D F
Mass Spectrometry Imaging Group, Pathology Sciences, Drug Safety & Metabolism, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom.
National Physical Laboratory, Teddington, United Kingdom; School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
Adv Cancer Res. 2017;134:133-171. doi: 10.1016/bs.acr.2016.11.005. Epub 2017 Jan 10.
Over the last decade mass spectrometry imaging (MSI) has been integrated in to many areas of drug discovery and development. It can have significant impact in oncology drug discovery as it allows efficacy and safety of compounds to be assessed against the backdrop of the complex tumour microenvironment. We will discuss the roles of MSI in investigating compound and metabolite biodistribution and defining pharmacokinetic -pharmacodynamic relationships, analysis that is applicable to all drug discovery projects. We will then look more specifically at how MSI can be used to understand tumour metabolism and other applications specific to oncology research. This will all be described alongside the challenges of applying MSI to industry research with increased use of metrology for MSI.
在过去十年中，质谱成像（MSI）已被应用于药物发现和开发的许多领域。它在肿瘤学药物发现中可产生重大影响，因为它能够在复杂的肿瘤微环境背景下评估化合物的疗效和安全性。我们将讨论MSI在研究化合物和代谢物生物分布以及确定药代动力学-药效学关系方面的作用，这些分析适用于所有药物发现项目。然后，我们将更具体地探讨MSI如何用于理解肿瘤代谢以及肿瘤学研究特有的其他应用。所有这些都将结合将MSI应用于工业研究时所面临的挑战进行描述，同时MSI的计量学应用也在不断增加。
